Dexlansoprazole Patent Expiration
Dexlansoprazole is Used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis. It was first introduced by Takeda Pharmaceuticals Usa Inc
Dexlansoprazole Patents
Given below is the list of patents protecting Dexlansoprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dexilant | US9233103 | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy | Mar 05, 2032 | Takeda Pharms Usa |
| Dexilant |
US8173158 (Pediatric) | Methods of treating gastrointestinal disorders independent of the intake of food | Sep 17, 2030 | Takeda Pharms Usa |
| Dexilant | US8173158 | Methods of treating gastrointestinal disorders independent of the intake of food | Mar 17, 2030 | Takeda Pharms Usa |
| Dexilant Solutab | US9241910 | Orally-disintegrating solid preparation | Mar 10, 2029 | Takeda Pharms Usa |
| Dexilant Solutab |
US8871273 (Pediatric) | Method for producing granules | Jul 11, 2028 | Takeda Pharms Usa |
| Dexilant | US8871273 | Method for producing granules | Jan 11, 2028 | Takeda Pharms Usa |
| Dexilant Solutab | US8871273 | Method for producing granules | Jan 11, 2028 | Takeda Pharms Usa |
| Dexilant |
US8105626 (Pediatric) | Granules containing acid-unstable chemical in large amount | Mar 27, 2027 | Takeda Pharms Usa |
| Dexilant |
US7790755 (Pediatric) | Controlled release preparation | Feb 02, 2027 | Takeda Pharms Usa |
| Dexilant | US8105626 | Granules containing acid-unstable chemical in large amount | Sep 27, 2026 | Takeda Pharms Usa |
| Dexilant | US7790755 | Controlled release preparation | Aug 02, 2026 | Takeda Pharms Usa |
| Dexilant |
US8461187 (Pediatric) | Multiple PPI dosage form | Jul 17, 2026 | Takeda Pharms Usa |
| Dexilant Solutab |
US8461187 (Pediatric) | Multiple PPI dosage form | Jul 17, 2026 | Takeda Pharms Usa |
| Dexilant | US9011926 | Method for producing granules | Feb 24, 2026 | Takeda Pharms Usa |
| Dexilant Solutab | US9011926 | Method for producing granules | Feb 24, 2026 | Takeda Pharms Usa |
| Dexilant | US8461187 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant | US9238029 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant Solutab | US8461187 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant Solutab | US9238029 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant |
US8722084 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant |
US8784885 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US8784885 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant | US8722084 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant | US8784885 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US8784885 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6664276 (Pediatric) | Benzimidazole compound crystal |
Jul 30, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6664276 | Benzimidazole compound crystal |
Jan 30, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6664276 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6462058 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6664276 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6939971 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US9145389 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6462058 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6939971 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US9145389 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6238994 (Pediatric) | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6328994 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7431942 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7875292 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6328994 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7431942 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7875292 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7399485 (Pediatric) | Rapidly Disintegrable solid preparation |
Nov 26, 2018
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7399485 | Rapidly Disintegrable solid preparation |
May 26, 2018
(Expired) | Takeda Pharms Usa |
Dexlansoprazole's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List